Literature DB >> 21808832

Resource allocation for pharmaceutical procurement in the Brazilian Unified Health System.

Fabiola Sulpino Vieira1, Paola Zucchi.   

Abstract

OBJECTIVE: To analyze resource allocation for pharmaceutical procurement by federative entities in the Brazilian Unified Health System.
METHODS: The amounts allocated to purchase pharmaceuticals during 2009 in two information systems were analyzed: Siga Brasil (Follow Brazil) for national data and Sistema de Informações sobre Orçamentos Públicos em Saúde (Information System on Public Health Budgets) for states, the Federal District and municipalities data. Per capita spending and the mean and median spending were calculated by municipalities, according to region and population size. The Spearman correlation coefficient was calculated for some variables. The statistical analysis included tests of normality and multiple comparisons for differences between groups.
RESULTS: In 2009 the total amount spent by the three spheres of government for purchase of medicines was approximately R$ 8.9 billion. States and the Federal District were the main players, accounting for 47.1% of the total amount spent in the health system. Some states had per capita spending well above the mean (R$ 22.00 per resident/year) and the median (R$ 17.00 per resident/year). There were differences in municipal spending by region. The mean per capita expenditure of municipalities with less than 5,000 residents was 3.9 times that of municipalities with over 500,000 residents. Municipalities with less than 10,000 residents had higher per capita spending than other municipalities.
CONCLUSIONS: Economic aspects such as the scale of procurement and bargaining power may explain differences in per capita spending between federal entities, especially among municipalities. The study indicates inefficiencies in the use of financial resources to procure medicines in the Brazilian Unified Health System.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21808832     DOI: 10.1590/s0034-89102011005000048

Source DB:  PubMed          Journal:  Rev Saude Publica        ISSN: 0034-8910            Impact factor:   2.106


  7 in total

1.  Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?

Authors:  Andréa Dâmaso Bertoldi; Ana Paula Helfer; Aline L Camargo; Noêmia U L Tavares; Panos Kanavos
Journal:  Global Health       Date:  2012-03-21       Impact factor: 4.185

2.  Congenital toxoplasmosis in the state of Minas Gerais, Brazil: a neglected infectious disease?

Authors:  E V M Carellos; W T Caiaffa; G M Q Andrade; M N S Abreu; J N Januário
Journal:  Epidemiol Infect       Date:  2013-07-03       Impact factor: 4.434

3.  Costs of Public Pharmaceutical Services in Rio de Janeiro Compared to Farmácia Popular Program.

Authors:  Rondineli Mendes da Silva; Rosângela Caetano
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

4.  Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.

Authors:  Tatiana Chama Borges Luz; Claudia Garcia Serpa Osorio-de-Castro; Rachel Magarinos-Torres; Bjorn Wettermark
Journal:  PLoS One       Date:  2017-04-07       Impact factor: 3.240

5.  Corporate social responsibility to improve access to medicines: the case of Brazil.

Authors:  Halla Thorsteinsdóttir; Natasha Ovtcharenko; Jillian Clare Kohler
Journal:  Global Health       Date:  2017-02-21       Impact factor: 4.185

6.  Infrastructure of pharmacies of the primary health care in the Brazilian Unified Health System: Analysis of PNAUM - Services data.

Authors:  Silvana Nair Leite; Fernanda Manzini; Juliana Álvares; Augusto Afonso Guerra; Ediná Alves Costa; Francisco de Assis Acurcio; Ione Aquemi Guibu; Karen Sarmento Costa; Margô Gomes de Oliveira Karnikowski; Orlando Mário Soeiro; Mareni Rocha Farias
Journal:  Rev Saude Publica       Date:  2017-11-13       Impact factor: 2.106

7.  Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.

Authors:  Jillian Clare Kohler; Nicholas Mitsakakis; Faridah Saadat; Danalyn Byng; Martha Gabriela Martinez
Journal:  Global Health       Date:  2015-08-04       Impact factor: 4.185

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.